Login
Companies $EXEL
$65.99 -$1.11 (1.65%) After hours
EXELIXIS, INC. logo

EXELIXIS, INC.

exelixis.com

What Do They Do?

Sells cancer medicines, including CABOMETYX and COMETRIQ, through specialty distributors and pharmacies, and develops additional cancer treatments.

Who Are Their Customers?

Specialty distributors and specialty pharmacy providers buy Exelixis products and resell them to health care providers and patients. Outside the U.S., Ipsen and Takeda handle commercialization and distribution of CABOMETYX, while Ipsen handles COMETRIQ.

Customers above 10% of revenue, FY2025
of revenue from six customers (22%, 19%, 15%, 12%, 10%, 7%)
FY2023: 81% from six customers

Do Revenues Turn Into Profits?

Yes. It kept 34 cents of every revenue dollar as net income in FY2025 and turned 38 cents into free cash flow.

Operating income, FY2025
38% of revenue
▲ +44% vs FY2024 ($604.6M, 28%)
Net income, FY2025
34% of revenue
▲ +50% vs FY2024 ($521.3M, 24%)
Free cash flow, FY2025
38% of revenue
▲ +30% vs FY2024 ($671.5M, 31%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Oct 2, 2026
Revenue
▲ +10%
vs $597.8M in Q3 FY2025
Net income
▲ +13%
vs $193.6M in Q3 FY2025
Net product revenues share of revenue vs 90.8% in Q3 FY2025

Additional cancer indications The latest report includes CABOMETYX for previously treated pancreatic and extra-pancreatic neuroendocrine tumors; the older report listed renal, liver, differentiated thyroid and medullary thyroid cancers.

Zanzalintinib advances Zanzalintinib has moved from a clinical-stage pipeline asset to an FDA-reviewed candidate for certain colorectal cancers, with a late-stage development program in other indications.

Revenue over time
Net product revenues Collaboration services revenues Gross product revenues Collaboration services revenues Discounts and allowances License revenues
$2.5B$1.3B$0

Who Do They Compete With?

Competes with Merck &, Pfizer, BMS, Eisai, Novartis, Bayer, Blueprint Medicine, Roche, Eli Lilly, Lantheus Holdings, POINT Biopharma, Curium US, ITM Solucin, and Genzyme

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support